Testing a new medication for kidney cancer that has spread to bones

Plain-English translation of NCT07043608 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new drug called for people with advanced kidney cancer (specifically clear cell type) that has spread to their bones. You would take the medication as a daily pill alongside a bone-strengthening agent. The study wants to see if this treatment can slow down cancer growth and improve survival in people whose cancer did not respond well enough to immune therapy they received previously.

Kidney cancer that spreads to bones is particularly difficult to treat and often stops responding to immune-based therapies that doctors use first. This trial exists to find out whether this medication might help people in that situation by working through a different mechanism to fight the cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic clear cell kidney cancer that cannot be surgically removed
you have at least three areas of cancer in your bones that show up on imaging
you have already received 1–3 prior treatments (including immune checkpoint inhibitor therapy) for your kidney cancer
you are 18 years or older
you have seen a dentist within the past 90 days and been cleared to receive bone-strengthening treatments
your blood work and organ function tests are within acceptable ranges

You likely don't qualify if…

you have not previously received immune checkpoint inhibitor therapy as part of your cancer treatment
you have serious liver or kidney function problems that exceed the study thresholds
you do not have enough healthy bone marrow cells (low blood counts)
you have not had a recent dental evaluation or were not cleared by a dentist for bone-strengthening agents

What participation looks like

You would take as a 100 mg pill by mouth once daily in 28-day treatment cycles, starting immediately and continuing as long as the treatment is working and you can tolerate it. Within 30 days of starting, you would also begin a bone-strengthening medication chosen by your doctor. The study team will monitor you with regular blood tests and imaging scans to check how your cancer is responding, and you may be followed for survival outcomes for up to 24 months.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California